{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"12","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"All patients will have their tumor measurements recorded at baseline and at the time of each MRI scan. Lesions must be measured in two dimensions. The dose of gadolinium must be held constant from scan to scan. Macdonald criteria will be used for assessment of tumor response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.","id":"OG000","title":"Temozolomide"}],"paramType":"MEDIAN","populationDescription":"Glioblastoma patients","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}